161 related articles for article (PubMed ID: 27138793)
1. Phospho-Aspirin (MDC-22) Prevents Pancreatic Carcinogenesis in Mice.
Mattheolabakis G; Papayannis I; Yang J; Vaeth BM; Wang R; Bandovic J; Ouyang N; Rigas B; Mackenzie GG
Cancer Prev Res (Phila); 2016 Jul; 9(7):624-34. PubMed ID: 27138793
[TBL] [Abstract][Full Text] [Related]
2. Phospho-Aspirin (MDC-22) inhibits pancreatic cancer growth in patient-derived tumor xenografts and KPC mice by targeting EGFR: Enhanced efficacy in combination with irinotecan.
Rodriguez Lanzi C; Wei R; Luo D; Mackenzie GG
Neoplasia; 2022 Feb; 24(2):133-144. PubMed ID: 34968866
[TBL] [Abstract][Full Text] [Related]
3. A novel Ras inhibitor (MDC-1016) reduces human pancreatic tumor growth in mice.
Mackenzie GG; Bartels LE; Xie G; Papayannis I; Alston N; Vrankova K; Ouyang N; Rigas B
Neoplasia; 2013 Oct; 15(10):1184-95. PubMed ID: 24204197
[TBL] [Abstract][Full Text] [Related]
4. Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress.
Huang L; Wong CC; Mackenzie GG; Sun Y; Cheng KW; Vrankova K; Alston N; Ouyang N; Rigas B
BMC Cancer; 2014 Feb; 14():141. PubMed ID: 24575839
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of pancreatic intraepithelial neoplasia progression to carcinoma by nitric oxide-releasing aspirin in p48(Cre/+)-LSL-Kras(G12D/+) mice.
Rao CV; Mohammed A; Janakiram NB; Li Q; Ritchie RL; Lightfoot S; Vibhudutta A; Steele VE
Neoplasia; 2012 Sep; 14(9):778-87. PubMed ID: 23019409
[TBL] [Abstract][Full Text] [Related]
6. Phospho-valproic acid inhibits pancreatic cancer growth in mice: enhanced efficacy by its formulation in poly-(L)-lactic acid-poly(ethylene glycol) nanoparticles.
Mattheolabakis G; Wang R; Rigas B; Mackenzie GG
Int J Oncol; 2017 Oct; 51(4):1035-1044. PubMed ID: 28849098
[TBL] [Abstract][Full Text] [Related]
7. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications.
Kodela R; Chattopadhyay M; Velázquez-Martínez CA; Kashfi K
Biochem Pharmacol; 2015 Dec; 98(4):564-72. PubMed ID: 26394025
[TBL] [Abstract][Full Text] [Related]
8. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds.
Huang L; Mackenzie GG; Sun Y; Ouyang N; Xie G; Vrankova K; Komninou D; Rigas B
Cancer Res; 2011 Dec; 71(24):7617-27. PubMed ID: 22025561
[TBL] [Abstract][Full Text] [Related]
10. Early requirement of Rac1 in a mouse model of pancreatic cancer.
Heid I; Lubeseder-Martellato C; Sipos B; Mazur PK; Lesina M; Schmid RM; Siveke JT
Gastroenterology; 2011 Aug; 141(2):719-30, 730.e1-7. PubMed ID: 21684285
[TBL] [Abstract][Full Text] [Related]
11. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
[TBL] [Abstract][Full Text] [Related]
12. A novel tricarbonylmethane agent (CMC2.24) reduces human pancreatic tumor growth in mice by targeting Ras.
Mallangada NA; Vargas JM; Thomas S; DiGiovanni MG; Vaeth BM; Nemesure MD; Wang R; LaComb JF; Williams JL; Golub LM; Johnson F; Mackenzie GG
Mol Carcinog; 2018 Sep; 57(9):1130-1143. PubMed ID: 29683208
[TBL] [Abstract][Full Text] [Related]
13. Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin.
Sclabas GM; Uwagawa T; Schmidt C; Hess KR; Evans DB; Abbruzzese JL; Chiao PJ
Cancer; 2005 Jun; 103(12):2485-90. PubMed ID: 15861417
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
[TBL] [Abstract][Full Text] [Related]
15. Utility Of Nitric Oxide And Hydrogen Sulfide-Releasing Chimeras As Anticancer Agents.
Kashfi K
Redox Biol; 2015 Aug; 5():420. PubMed ID: 28162289
[TBL] [Abstract][Full Text] [Related]
16. Acinar-to-ductal metaplasia accompanies c-myc-induced exocrine pancreatic cancer progression in transgenic rodents.
Grippo PJ; Sandgren EP
Int J Cancer; 2012 Sep; 131(5):1243-8. PubMed ID: 22024988
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model.
Ouyang N; Williams JL; Tsioulias GJ; Gao J; Iatropoulos MJ; Kopelovich L; Kashfi K; Rigas B
Cancer Res; 2006 Apr; 66(8):4503-11. PubMed ID: 16618778
[TBL] [Abstract][Full Text] [Related]
18. Phospho-aspirin-2 (MDC-22) inhibits estrogen receptor positive breast cancer growth both in vitro and in vivo by a redox-dependent effect.
Huang L; Wong CC; Cheng KW; Rigas B
PLoS One; 2014; 9(11):e111720. PubMed ID: 25369051
[TBL] [Abstract][Full Text] [Related]
19. The Anticancer Effects of Novel α-Bisabolol Derivatives Against Pancreatic Cancer.
Murata Y; Kokuryo T; Yokoyama Y; Yamaguchi J; Miwa T; Shibuya M; Yamamoto Y; Nagino M
Anticancer Res; 2017 Feb; 37(2):589-598. PubMed ID: 28179305
[TBL] [Abstract][Full Text] [Related]
20. NF-kappaB, inflammation and pancreatic carcinogenesis: NF-kappaB as a chemoprevention target (review).
Zhang Z; Rigas B
Int J Oncol; 2006 Jul; 29(1):185-92. PubMed ID: 16773199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
